DrugPatentWatch Database Preview
Nextwave Pharms Company Profile
What is the competitive landscape for NEXTWAVE PHARMS, and what generic alternatives to NEXTWAVE PHARMS drugs are available?
NEXTWAVE PHARMS has two approved drugs.
There are twelve US patents protecting NEXTWAVE PHARMS drugs.
Summary for Nextwave Pharms
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Nextwave Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-002 | Dec 4, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-002 | Dec 4, 2015 | RX | Yes | No | 8,202,537 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | 8,778,390 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | 8,999,386 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-002 | Dec 4, 2015 | RX | Yes | No | 9,844,544 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | 9,040,083 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for NEXTWAVE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Oral Suspension | 5 mg/mL | ➤ Subscribe | 2013-08-02 |
International Patents for Nextwave Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2009530298 | ➤ Sign Up |
| Israel | 227734 | ➤ Sign Up |
| Australia | 2007227569 | ➤ Sign Up |
| Russian Federation | 2008140944 | ➤ Sign Up |
| Spain | 2378573 | ➤ Sign Up |
| Canada | 2645855 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
